|
|
Friends of Israel
Urological Symposium
Tel Aviv Hilton, Tel-Aviv, Israel, July 3-5, 2012
| Scientific Program |
 |
|
|
| 18:30-20:00 |
Prostate Cancer Symposium
Supported by Ferring Canada & Ferring Israel
|
|
18:30-18:40
|
Welcome and Introduction
L. Klotz, Canada & J. Ramon, Israel
FOIU Congress co-chairpersons
|
| 18:40-19:00 |
The future of active surveillance
L. Klotz, Canada
|
| 19:00-19:20 |
GnRH antagonists vs. GnRH agonists: What is the difference?
J. Pinthus, Canada
|
|
19:20-20:00 |
Panel discussion: Practical management of patients on hormonal therapy
-When should Testosterone be measured?
-What is an adequate castration?
-Is intermittent hormonal therapy oncologically safe?
-Is there a place to revive the concept of neo-adjuvant hormonal therapy prior to surgery?
-Medical castration: At what intervals should depot be given?
Moderators: L. Klotz, Canada & J. Pinthus, Canada
Panel:
M. Cher, USA
N. Fleshner, Canada
M. Frydenberg, Australia
E. Rosenbaum, Israel
A. Sella, Israel
|
| 20:00 |
Get-Together
|
|
|
20:30
Guest Lecture
Aluf (Major General, res.) Amos Yadlin
"Israel's defense challenges"
|
|
Hall A
08:30-10:30
|
Prostate Cancer - 10-20 years from now
Chairpersons: L. Klotz, Canada & R. Reiter, USA |
|
Based on my knowledge and experience, my educated guess is that in 10-20 years:
|
|
08:30-09:10
|
Screening and prevention
PSA will no longer be used for screening
Yes: E. Klein, USA
No: S. Loeb, USA
Prostate cancer prevention will be dead
Yes: M. Litwin, USA
No: N. Fleshner, Canada
|
| 09:10-09:20 |
5-Alpha reductase inhibitors will disappear due to concern about high-grade prostate cancer
R. Reiter, USA
|
| 09:20-09:35 |
The modified Gleason’s grading system will be re-modified and Gleason’s pattern 3 will no longer be considered “cancer”
J. Srigley, Canada
|
|
09:35-09:55
|
Active surveillance will be promoted to patients with Gleason’s 7 (3+4)
Yes: L. Klotz, Canada
No: M. Soloway, USA
|
|
09:55-10:05 |
Radical prostatectomy
Open radical prostatectomy will continue to be a common operation
M. Zerbib, France
|
| 10:05-10:15 |
Robotic radical prostatectomy will replace laparoscopic and open radical prostatectomy
C. Abbou, France
|
| 10:15-10:30 |
Focal and ablative treatment
Focal treatment will be widely accepted and utilized
A. Villers, France
Cryotherapy will be used for salvage only
A. Belldegrun, USA
HIFU will remain a “niche” treatment
Yes: J. Nelson, USA
No: I. Grunberger, USA
|
|
Hall B
08:30-09:30
|
Pediatric Urology
Chairpersons: J. Kaneti, Israel & J. Elder, USA |
|
08:30-08:45
|
Progress in hypospadias repair
W. Snodgrass, USA
|
| 08:45-09:00 |
Urologic malignancies in children: Long-term implications for adults
J. Elder, USA
|
| 09:00-09:30 |
Vesicoureteral reflux:
-Conflicting guidelines for treatment
-Endoscopic treatment
-Recurrent UTI's in females who had V-U reflux in childhood: Incidence, etiology and management
Moderator: J. Elder, USA
Panel
B. Chertin, Israel
P. Livne, Israel
Y. Mor, Israel
W. Snodgrass, USA
|
|
Hall B
09:30-10:30
|
Trauma and Reconstruction
Chairperson: M. Coburn, USA & O. Shenfeld, Israel |
|
09:30-09:50
|
Simulation as a cultural change vehilcle in emergency preparedness training and patient safety education
A. Ziv, Israel
The Israel Center for Medical Simulation (MSR)
|
| 09:50-10:30 |
Controversies in uretheral trama and reconstruction
Moderator: O. Shenfeld, Israel
Panel
J. Borin, USA
M. Coburn, USA
J. Elder, USA
R.P. Terlecki, USA
|
| 10:30-11:00 |
Coffee Break, Poster Viewing and Visit Exhibition
|
|
Hall A
11:00-12:00
|
Guest Speakers
Chairperson: J. Ramon, Israel |
|
11:00-11:30
|
Teva & Medicine - The covenant between Teva and our patients
Prof. Moshe Many
Vice-Chairman, Teva Pharmaceutical Industries Ltd, former president of Tel Aviv University
&
Dr. Jeremy Levin
President & CEO, Teva Pharmaceutical Industries, Ltd
|
|
11:30-12:00 |
Top disruption or Bottom disruption in the Medical Device industry
Kobi Richter, PhD
Founder and chair of Medinol
|
| |
|
|
Hall A
12:00-13:00
|
OAB & Incontinence
Supported by Pfizer Israel
Chairpersons: G. Gillon, Israel & D. Staskin, USA |
|
12:00-12:20
12:20-13:00
|
Is there a best anti-muscarinic drug?
J. Golomb, Israel
Managing the anti-muscarinic non-responders
Sacral neuro-stimulation
M. Guralnick, USA
Botox
D. Staskin, USA
Clam enterocystoplasty
H. Goldman, USA
|
|
Hall B
12:00-13:00
|
Bladder Cancer
Chairpersons: A. Stein, Israel & M. Zerbib, France |
|
12:00-12:10
|
Urothelial cancer biomarkers: Role in diagnosis and treatment decisions
S. Lerner, USA
|
|
12:10-12:20
12:20-13:00 |
High-grade T1 urothelial cancer of bladder
The role of pathology review of TURBT specimen
E. Oliva, USA
Case Discussion on high grade T1 tumor
-Role of restaging
-BCG failure
-Primary cystectomy
-Novel treatments
Moderator: M. Soloway, USA
Panel
J. Baniel, Israel
S. Lerner, USA
A. Stein, Israel
M. Zerbib, France
|
| 13:00-14:00 |
Lunch Break
|
|
Session 7
Hall A
14:00-15:30
|
LUTS/BPH & Erectile Dysfunction: Links for casual relationship, management and treatment
Supported by Eli Lilly Israel
Chairpersons: S. Glina, Brazil & Y. Vardi, Israel
|
|
14:00-14:15
14:15-14:45
14:45-15:00
15:00-15:10
15:10-15:30 |
Pathogenic mechanisms linking BPH/LUTS and ED
S. Glina, Brazil
Impact of therapies for LUTS on ED
Medications
A. Greenstein, Israel
Surgery
E.F. Becher, Argentina
Impact of therapies for ED on LUTS
J. Chen, Israel
The rational for treating LUTS/BPH with PDE5-Is
Studies on the use of PDE5-Is for LUTS
Y. Vardi, Israel
Future directions
S. Glina, Brazil & Y. Vardi, Israel
|
|
Hall B
14:00-15:30
|
Kidney Cancer
Chairpersons: O. Nativ, Israel & J. Nelson, USA |
|
14:00-14:20
|
Highlights from the ISUP Consensus Conference on Adult Renal Tumor
B. Delahunt, New Zealand
|
|
14:20-14:40
14:40-15:00
15:00-15:30 |
Renal parenchimal preservation: How important is it?
O. Nativ, Israel
When should we suggest a radical nephrectomy?
M.-O. Timsit, France
Small renal mass
-Role of biopsy
-Role of surveillance
-Ablation
-Nephron-sparing surgery
-Role of robot surgery
-Role of TKI’s
Moderator: A. Zisman, Israel
Panel
A. Belldegrun, USA
G. Bratslavsky, USA
E. Klein, USA
O. Nativ, Israel
M.-O. Timsit, France
|
| 15:30-16:00 |
Coffee Break, Poster Viewing and Visit Exhibition
|
|
Hall A
16:00-17:30
|
Advanced Kidney Cancer
Chairpersons: S. Lerner, USA & A. Sella, Israel |
16:00-16:15
16:15-16:30
16:30-16:40
16:40-17:00
17:00-17:30
|
Management of IVC involvement
A. Saglowsky, USA
Kidney cancer surgery in the era of targeted cancer therapy
A. Belldegrun, USA
Update on neoadjuvant treatment
A. Sella, Israel
The therapy of metastatic RCC
G. Bratslavsky, USA
Case Discussion
Moderator: S. Lerner, USA
Panel
A. Belldegrun, USA
R. Berger, Israel
G. Bratslavsky, USA
A. Saglowsky, USA
A. Sella, Israel
A. Zisman, Israel
|
|
Hall B
16:00-17:30
|
Robotic Surgery: Radical prostatectomy
Supported by Dover
Chairpersons: D. Kakiashvili, Israel & A. Shalhav, USA
|
|
16:00-16:15
16:15-17:30
|
Learning curve of robot-assisted laparoscopic radical prostatectomy
C. Abbou, France
A. Shalhav, USA
P. Stricker, Australia
Nerve-sparing radical prostatectomy: How I do it
Bladder neck dissection and dissection of seminal vesicles
C. Abbou, France
L. Goldenberg, Canada
D. Pushkar, Russia
P. Stricker, Australia
A. Tewari, USA
Nerve-sparing extirpation of the prostate
C. Abbou, France
L. Goldenberg, Canada
D. Pushkar, Russia
P. Stricker, Australia
A. Tewari, USA
Each speaker shall present his technique in a 5-minute video presentation for each topic
|
| 17:30-18:30 |
Moderated Poster Session
Chairpersons: E. Klein, USA & H. Winkler, Israel
|
|
17:30-17:36
|
Management of B.C.G. non-responders with fixed dose intravesical gemcitabine in superficial T.C.C. of urinary bladder
N. Mohanty, India
|
| 17:36-17:42 |
Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (ACTOS) use
R.P. Terlecki, USA
|
| 17:42-17:48 |
Using micro-RNA expression to predict response to neo-adjuvant chemotherapy in urothelial carcinoma of the bladder - preliminary results and future plans
R. Leibowitz-Amit, Israel
|
| 17:48-17:54 |
A new microRNA-based diagnostic test for classification of kidney tumors
Z. Dotan, Israel
|
| 17:54-18:00 |
Prostate specific antigen/solvent interaction analysis (PSA/SIA): Continued examination of potential PSA isoforms for a new assay for prostate cancer
M. Stovsky, USA
|
| 18:00-18:06 |
A biopsy-based genomic approach to selecting men for active surveillance
E. Klein, USA
|
| 18:06-18:12 |
Hyperbaric oxygen therapy assessment in case of hemorrhagic cystitis after radiotherapy
W. Polom, Poland
|
| 18:12-18:18 |
Patient Perceived Outcomes after the AdVance male sling procedure for post-prostatectomy incontinence
E. Rijo, Spain
|
| 18:18-18:24 |
Influence of strict sperm morphology on the results of classic in vitro fertilization
S. Glina, Brazil
|
| 18:24-18:30 |
Cytokines in urine indicates urethral origin of urgency in the "overactive bladder syndrome"
O. Löfgren, Sweden
|
|
Hall A
08:30-10:30
|
ED/SD
Supported by Eli Lilly Israel
Chairpersons: A. Greenstein, Israel & J. Rajfer, USA |
|
|
Does sexual dysfunction and OAB / LUTS share a common physiological basis?
S. Glina, Brazil
|
| 08:45-09:00 |
Shockwave treatment for ED: Is there a potential for cure?
Y. Vardi, Israel
|
| 09:00-10:00 |
Rehabilitation of sexual function after prostate cancer therapy:
Is there a difference in the management between radical prostatectomy and irradiation?
Moderator: J. Rajfer, USA
Panel
E.F. Becher, Argentina
J. Chen, Israel
S. Glina, Brazil
B. Kava, USA
|
| 10:00-10:15 |
Which treatment for ED patients with testosterone deficiency
E.F. Becher, Argentina
|
|
10:15-10:30
|
Discussion
|
|
Hall B
08:30-09:30
|
Bladder Cancer
Chairpersons: D. Pode, Israel & M. Soloway, USA |
|
|
Evolution of continent urinary diversion: Practical tips in construction and management
A. Sagalowsky, USA
|
| 09:00-09:15 |
Why we still divert the urine to conduits?
I. Leibovitch, Israel
|
| 09:15-10:30 |
Critical assessment of neo-adjuvant and adjuvant chemotherapy in muscle invasive urothelial carcinoma
Moderator: D. Pode, Israel
Panel
Z. Dotan, Israel
E. Gez, Israel
E. Klein, USA
S. Lerner, USA
M. Zerbib, France
|
|
Hall B
09:30-10:30 |
Male Urinary Incontinence
Chairpersons: J. Olsburgh, UK & S.V. Romano, Aregentina |
|
09:30-09:40
|
Incontinence following radiation therapy for prostate cancer
M. Wygoda, Israel
|
09:40-10:10
10:10-10:30 |
Post prostatectomy incontinence: Surgical options
Male sling
S.V. Romano, Argentina
ProAct balloons
I. Grunwald, Israel
Artificial urinary sphincter
S. Herschorn, Canada
Case discussion
Moderator: Y. Vardi, Israel
Panel
S. Herschorn, Canada
D. Pode, Israel
S.V. Romano, Argentina
M. Wygoda, Israel
|
| 10:30-11:00 |
Coffee Break, Poster Viewing and Visit Exhibition
|
|
Hall A
11:00-12:00
|
Guest Speakers
Chairperson: J. Ramon, Israel |
|
11:00-11:30
|
Limits of life expectancy? Lessons from ribosome research
Prof. Ada Yonath
Weizman Institute of Science, recipient of the Nobel Prize in Chemistry, 2009
|
|
11:30-12:00 |
Israel's outlook on The Arab Spring
Prof. Itamar Rabinovich
Israel's former ambassador in Washington DC and former president of the Tel Aviv University
|
| |
|
|
Hall A
12:00-13:00
|
Prostate Cancer
Chairpersons: M. Wygoda, Israel & M. Zelevsky, USA |
|
12:00-12:20
|
Radiation hormonal therapy for intermediate risk prostate cancer: Is the survival benefit outweighed by the side-effects?
Combination therapy
M. Zelevsky, USA
Radiation alone
Z. Symon, Israel
|
| 12:20-13:00 |
Positive surgical margins in radical prostatectomy
Pathological issues
J. Srigley, Canada
Incidence
O. Yossepowitch, Israel
Oncological impact
M. Cher, USA
Role of MRI
A. Villers, France
Adjuvant therapy
M. Wygoda, Israel
Surveillance and salvage therapy
O. Yossepowitch, Israel
Is there a gold standard for post-prostatectomy irradiation?
M. Zelevsky, Israel
|
|
Hall B
12:00-13:00
|
Testicular Cancer
Chairpersons: E. Gez, Israel & J. Sheinfeld, USA |
|
12:00-12:15
|
Any role for an adjuvant treatment in stage-1 seminoma?
R. Berger, Israel
|
| 12:15-12:30 |
Is there a role for primary RPLND for stage-1 nonseminoma?
J. Sheinfeld, USA
|
| 12:30-13:00 |
Testicular-sparing surgery
-When?
-In whom?
-Surgical aspects
-Role of frozen section
-Adjuvant treatment
Moderator: J. Sheinfeld, USA
Panel
J. Baniel, Israel
R. Berger, Israel
E. Gez, Israel
I. Leibovitch, Israel
E. Oliva, USA
A. Sella, Israel
|
| 13:00-14:00 |
Lunch Break
|
|
Hall A
14:00-15:30
|
Robotic Surgery: Cystectomy and renal surgery
Supported by Dover
Chairpersons: C. Abbou, France & O. Gofrit, Israel
|
|
14:00-14:45
|
Robotic partial nephrectomy
-Tips & tricks for the beginning console surgeon
-Selective arterial clamping
-Suturing techniques for closure of the collecting system
-Closure and approximation of the renal parenchyma
-Single-port nephrectomy
-Review on results and complications
Moderator: C. Abbou, France
Panel
G. Amiel, USA
J. Borin, USA
A. Shalhav, USA
D. Zilberman, Israel
|
|
14:45-15:30
|
Robotic radical cystectomy
-Tips & tricks for nerve sparing cystecomty
-Lymphadenectomy: Modified vs. Extensive
-Intracorporeal vs. Extracorporeal urinary diversion
-Review on robotic-induced complications
-Reivew on oncological outcomes
Moderator: A. Shalhav, USA
Panel
C. Abbou, France
G. Amiel, USA
O. Gofrit, Israel
R. Reiter, USA
|
|
Hall B
14:00-15:30
|
Pelvic Organ Prolapse and Incontinence
Chairpersons: J. Golomb, Israel & D. Pushkar, Russia |
|
14:00-14:15
|
Female pelvic floor disorders: Recognizing the problem
S. Herschorn, Canada
|
| 14:15-15:30 |
Pelvic organ prolapse
-Conservative management
-Operative management:
Vaginal approach vs. Abdominal approach
To sling or not to sling?
Surgical tips and tricks
Moderator: H. Goldman, USA
Panel
J. Golomb, Israel
S. Herschorn, Canada
D. Pushkar, Russia
D. Staskin, USA
|
| 15:30-16:00 |
Coffee Break, Poster Viewing and Visit Exhibition
|
|
Hall A
16:00-17:30
|
Prostate Cancer: Castrate resistant
Chairpersons: A. Lindner, Israel & M. Litwin, USA |
|
16:00-16:20
16:20-16:40
|
Overview of new agents
M. Cher, USA
Abiraterone and MDV3100 data
A. Belldegrun, USA
|
| 16:40-17:20 |
What are the most pressing questions for clinical trials?
Moderator: A. Lindner, Israel & A. Sella, Israel
Panel
E. Klein, USA
L. Klotz, Canada
M. Litwin, USA
J. Nelson, USA
J. Pinthus, Canada
A. Villers, France
|
|
17:20-17:30 |
Bone health, pain control and palliation in patients with bone metastasis
E. Gez, Israel
|
|
Hall B
16:00-17:30
|
Infertility
Chairpersons: D. Golovsky, Australia & L. Ross, USA |
|
16:00-16:15
16:15-16:30
16:30-16:45
16:45-17:00
|
Male Reproduction as a Public Health Issue
L. Ross, USA
Testosterone Replacement in the Infertile Male
G. Raviv, Israel
Preservation of Fertility in Cancer Patients
S. Silber, USA
Posthumous reproduction
I. Rosenblum, Israel
|
|
17:00-17:30 |
"Why a Urologist" in the evaluation and treatment of the infertile couple
Moderator: D. Golovsky, Australia
Panel
E. Amar, France
S. Silber, USA
S. Glina, Brazil
|
|
|
|
|
|
WebStudio.co.il
